{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CNY", "exchange": "SHH", "shortName": "SHANGHAI FUDAN-ZHANGJIAN BIO-PH", "longName": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.", "messageBoardId": "finmb_8288321", "market": "cn_market", "marketState": "POSTPOST", "earningsTimestamp": 1679918176, "earningsTimestampStart": 1682679540, "earningsTimestampEnd": 1683201600, "trailingAnnualDividendRate": 0.07, "trailingPE": 71.230774, "trailingAnnualDividendYield": 0.0074309977, "epsTrailingTwelveMonths": 0.13, "sharesOutstanding": 703000000, "bookValue": 2.202, "fiftyDayAverage": 9.992, "fiftyDayAverageChange": -0.7319994, "fiftyDayAverageChangePercent": -0.07325855, "twoHundredDayAverage": 9.3894, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Asia/Shanghai", "exchangeTimezoneShortName": "CST", "gmtOffSetMilliseconds": 28800000, "esgPopulated": false, "regularMarketChangePercent": -1.6985122, "regularMarketPrice": 9.26, "regularMarketChange": -0.15999985, "regularMarketTime": 1683874804, "regularMarketDayHigh": 9.45, "regularMarketDayRange": "9.23 - 9.45", "regularMarketDayLow": 9.23, "regularMarketVolume": 3740225, "regularMarketPreviousClose": 9.42, "bid": 9.25, "ask": 9.26, "fullExchangeName": "Shanghai", "financialCurrency": "CNY", "regularMarketOpen": 9.42, "averageDailyVolume3Month": 4813598, "averageDailyVolume10Day": 4255571, "fiftyTwoWeekLowChange": 1.44, "fiftyTwoWeekLowChangePercent": 0.18414323, "fiftyTwoWeekRange": "7.82 - 11.49", "fiftyTwoWeekHighChange": -2.2299995, "fiftyTwoWeekHighChangePercent": -0.19408177, "fiftyTwoWeekLow": 7.82, "fiftyTwoWeekHigh": 11.49, "twoHundredDayAverageChange": -0.1293993, "twoHundredDayAverageChangePercent": -0.013781425, "marketCap": 7327122944, "priceToBook": 4.2052684, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.", "nameChangeDate": "2023-05-11", "firstTradeDateMilliseconds": 1592530200000, "priceHint": 2, "symbol": "688505.SS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Zhangjiang Hi-Tech Park", "address2": "No. 308 Cailun Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 5895 3355", "fax": "86 21 5855 3990", "website": "https://www.fd-zj.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.", "fullTimeEmployees": 910, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hai Bo  Wang", "age": 62, "title": "Co-Founder, Chairman & GM", "yearBorn": 1960, "fiscalYear": 2021, "totalPay": {"raw": 3255000, "fmt": "3.25M", "longFmt": "3,255,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Da Jun  Zhao", "age": 52, "title": "Co-Founder, Deputy GM & Exec. Director", "yearBorn": 1970, "fiscalYear": 2021, "totalPay": {"raw": 2623000, "fmt": "2.62M", "longFmt": "2,623,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yong  Su", "age": 58, "title": "Deputy GM & Exec. Director", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": {"raw": 2598000, "fmt": "2.6M", "longFmt": "2,598,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jun  Li", "age": 54, "title": "Co-Founder & Deputy GM", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Xue  Yan FCCA, HKICPA, ACCA, CICPA, CIA", "age": 40, "title": "CFO & Company Sec.", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Dai Qing  Yu", "age": 49, "title": "Quality Director & Employee Representative Supervisor", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}